We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Hospitals that take part in the 340B drug discount program almost quadrupled the price of cancer drugs in bills to patients with private insurance. Read More
Manufacturing is set to begin next year, when Emergent will begin production of “tens of millions of doses” of Providence’s investigational messenger RNA-based vaccine. Read More
“We believe in the value of science behind Eliquis and its therapeutic potential for patients, and the underlying intellectual property protecting these innovations,” the companies said in a joint statement. Read More
Heather Bresch — daughter of U.S. Sen. Joe Manchin (D-W.V.) and former CEO of Mylan — allegedly played a key role in squelching both a competing epinephrine self-injector and single-dose EpiPens, leaving pricey two-dose brand-name packs as patients’ only options, newly released court documents are claiming. Read More
Sanofi has dropped $1.9 billion to acquire New York-based Kadmon Pharmaceuticals and its first-in-class oral kinase inhibitor, Rezurock (belumosudil), approved in July to treat chronic graft-vs.-host disease (cGVHD). Read More
Roche has partnered with UK-based Adaptimmune Therapeutics to develop “off-the-shelf” T-cell therapies for up to five cancer targets in a deal valued at $150 million upfront but potentially worth up to $3 billion to the UK company. Read More
The FDA approved Aduhelm in early June, despite the drug showing only moderate benefit in one phase 3 trial and no benefit in another late-stage study. Read More